Suppr超能文献

sigma-1 受体的药理学。

The pharmacology of sigma-1 receptors.

机构信息

Team II Endogenous Neuroprotection in Neurodegenerative Diseases, INSERM U. 710, 34095 Montpellier Cedex 5, France.

出版信息

Pharmacol Ther. 2009 Nov;124(2):195-206. doi: 10.1016/j.pharmthera.2009.07.001. Epub 2009 Jul 18.

Abstract

Originally considered an enigmatic protein, the sigma-1 receptor has recently been identified as a unique ligand-regulated molecular chaperone in the endoplasmic reticulum of cells. This discovery causes us to look back at the many proposed roles of this receptor, even before its molecular function was identified, in many diseases such as methamphetamine or cocaine addiction, amnesia, pain, depression, Alzheimer's disease, stroke, retinal neuroprotection, HIV infection, and cancer. In this review, we examine the reports that have clearly shown an agonist-antagonist relationship regarding sigma-1 receptors in models of those diseases and also review the relatively known mechanisms of action of sigma-1 receptors in an attempt to spur the speculation of readers on how the sigma-1 receptor at the endoplasmic reticulum might relate to so many diseases. We found that the most prominent action of sigma-1 receptors in biological systems including cell lines, primary cultures, and animals is the regulation and modulation of voltage-regulated and ligand-gated ion channels, including Ca(2+)-, K(+)-, Na(+), Cl(-), and SK channels, and NMDA and IP3 receptors. We found that the final output of the action of sigma-1 receptor agonists is to inhibit all above-mentioned voltage-gated ion channels, while they potentiate ligand-gated channels. The inhibition or potentiation induced by agonists is blocked by sigma-1 receptor antagonists. Other mechanisms of action of sigma-1 receptors, and to some extent those of sigma-2 receptors, were also considered. We conclude that the sigma-1 and sigma-2 receptors represent potential fruitful targets for therapeutic developments in combating many human diseases.

摘要

最初被认为是一种神秘的蛋白质,σ-1 受体最近被鉴定为细胞内质网中一种独特的配体调节分子伴侣。这一发现促使我们回顾该受体的许多先前提出的作用,甚至在其分子功能被确定之前,就在许多疾病中,如甲基苯丙胺或可卡因成瘾、健忘症、疼痛、抑郁、阿尔茨海默病、中风、视网膜神经保护、HIV 感染和癌症。在这篇综述中,我们检查了那些在这些疾病的模型中明确显示 σ-1 受体激动剂-拮抗剂关系的报告,还回顾了相对已知的 σ-1 受体作用机制,试图激发读者对内质网中的 σ-1 受体如何与如此多的疾病相关的猜测。我们发现,σ-1 受体在包括细胞系、原代培养物和动物在内的生物系统中的最突出作用是调节和调制电压门控和配体门控离子通道,包括 Ca(2+)、K(+)、Na(+)、Cl(-)和 SK 通道,以及 NMDA 和 IP3 受体。我们发现,σ-1 受体激动剂作用的最终结果是抑制所有上述电压门控离子通道,同时增强配体门控通道。σ-1 受体拮抗剂可阻断激动剂诱导的抑制或增强作用。还考虑了 σ-1 受体的其他作用机制,在某种程度上也考虑了 σ-2 受体的作用机制。我们的结论是,σ-1 和 σ-2 受体代表了在对抗许多人类疾病的治疗开发中具有潜在价值的靶点。

相似文献

1
The pharmacology of sigma-1 receptors.
Pharmacol Ther. 2009 Nov;124(2):195-206. doi: 10.1016/j.pharmthera.2009.07.001. Epub 2009 Jul 18.
3
Sigma-1 receptor agonists directly inhibit Nav1.2/1.4 channels.
PLoS One. 2012;7(11):e49384. doi: 10.1371/journal.pone.0049384. Epub 2012 Nov 5.
4
Sigma-1 receptors and animal studies centered on pain and analgesia.
Expert Opin Drug Discov. 2015;10(8):885-900. doi: 10.1517/17460441.2015.1051961. Epub 2015 Jun 3.
5
Antagonist action of progesterone at σ-receptors in the modulation of voltage-gated sodium channels.
Am J Physiol Cell Physiol. 2011 Feb;300(2):C328-37. doi: 10.1152/ajpcell.00383.2010. Epub 2010 Nov 17.
6
Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction.
Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4993-5002. doi: 10.1167/iovs.08-1867. Epub 2008 Jul 18.
7
[Physiological functions of sigma-1 receptors and its relation to psychic dependence].
Nihon Arukoru Yakubutsu Igakkai Zasshi. 2012 Dec;47(6):279-86.
8
Sigma 1 receptor: a new therapeutic target for pain.
Eur J Pharmacol. 2013 Sep 15;716(1-3):78-93. doi: 10.1016/j.ejphar.2013.01.068. Epub 2013 Mar 13.
10
Sigma-1 receptor activation prevents intracellular calcium dysregulation in cortical neurons during in vitro ischemia.
J Pharmacol Exp Ther. 2006 Dec;319(3):1355-65. doi: 10.1124/jpet.106.107557. Epub 2006 Sep 20.

引用本文的文献

1
Choline-An Essential Nutrient with Health Benefits and a Signaling Molecule.
Int J Mol Sci. 2025 Jul 24;26(15):7159. doi: 10.3390/ijms26157159.
2
Sigma1 Receptor Modulates Plasma Membrane and Mitochondrial Peroxiporins.
Cells. 2025 Jul 15;14(14):1082. doi: 10.3390/cells14141082.
4
Pharmacological and Pathological Implications of Sigma-1 Receptor in Neurodegenerative Diseases.
Biomedicines. 2025 Jun 8;13(6):1409. doi: 10.3390/biomedicines13061409.
6
Recent Advances in the Development of Sigma Receptor (Radio)Ligands and Their Application in Tumors.
ACS Pharmacol Transl Sci. 2025 Mar 7;8(4):951-977. doi: 10.1021/acsptsci.4c00711. eCollection 2025 Apr 11.
7
The evolution of N, N-Dimethyltryptamine: from metabolic pathways to brain connectivity.
Psychopharmacology (Berl). 2025 Apr 11. doi: 10.1007/s00213-025-06777-z.
8
Preclinical Profile of CM699 as a Medication Candidate for Stimulant Use Disorder.
ACS Chem Neurosci. 2025 Apr 16;16(8):1454-1468. doi: 10.1021/acschemneuro.4c00589. Epub 2025 Mar 25.
9
SA4503 Mitigates Adriamycin-Induced Nephropathy via Sigma-1 Receptor in Animal and Cell-Based Models.
Pharmaceuticals (Basel). 2025 Jan 27;18(2):172. doi: 10.3390/ph18020172.

本文引用的文献

1
When the endogenous hallucinogenic trace amine N,N-dimethyltryptamine meets the sigma-1 receptor.
Sci Signal. 2009 Mar 10;2(61):pe12. doi: 10.1126/scisignal.261pe12.
2
The hallucinogen N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator.
Science. 2009 Feb 13;323(5916):934-7. doi: 10.1126/science.1166127.
3
Sigma-1 receptor knockout mice display a depressive-like phenotype.
Behav Brain Res. 2009 Mar 17;198(2):472-6. doi: 10.1016/j.bbr.2008.11.036. Epub 2008 Nov 30.
4
Sigma1 receptor antagonists determine the behavioral pattern of the methamphetamine-induced stereotypy in mice.
Psychopharmacology (Berl). 2009 May;203(4):781-92. doi: 10.1007/s00213-008-1425-z. Epub 2008 Dec 4.
6
DHEA-neuroprotection and -neurotoxicity after transient cerebral ischemia in rats.
J Cereb Blood Flow Metab. 2009 Feb;29(2):287-96. doi: 10.1038/jcbfm.2008.118. Epub 2008 Oct 15.
7
sigma-1 receptor modulation of acid-sensing ion channel a (ASIC1a) and ASIC1a-induced Ca2+ influx in rat cortical neurons.
J Pharmacol Exp Ther. 2008 Nov;327(2):491-502. doi: 10.1124/jpet.108.143974. Epub 2008 Aug 22.
8
Possible involvement of sigma-1 receptors in the anti-immobility action of bupropion, a dopamine reuptake inhibitor.
Fundam Clin Pharmacol. 2008 Aug;22(4):387-94. doi: 10.1111/j.1472-8206.2008.00605.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验